Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma.
Bollard
Catherine M
CM
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, 77030, USA. cmbollar@txccc.org
Huls
M Helen
MH
Buza
Elizabeth
E
Weiss
Heidi
H
Torrano
Vicky
V
Gresik
Mary V
MV
Chang
Jeff
J
Gee
Adrian
A
Gottschalk
Stephen M
SM
Carrum
George
G
Brenner
Malcolm K
MK
Rooney
Cliona M
CM
Heslop
Helen E
HE
D002051:Burkitt Lymphoma / Q000276:immunology / Q000628:therapy*; D005260:Female; D004854:Herpesvirus 4, Human / Q000276:immunology; D006689:Hodgkin Disease / Q000276:immunology / Q000628:therapy* / Q000821:virology; D006801:Humans; D016219:Immunotherapy, Adoptive; D008297:Male; D009687:Nuclear Proteins / Q000276:immunology*; D010750:Phosphoproteins / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology / Q000637:transplantation*
D009687:Nuclear Proteins; D010750:Phosphoproteins; C118485:latent nuclear antigen (LNA)